Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resting state connectivity within the basal ganglia and gait speed in older adults with cerebral small vessel disease and locomotor risk factors.

NeuroImage. Clinical·2020
Same author

Community-dwelling adults with a history of falling report lower perceived postural stability during a foam eyes closed test than non-fallers.

Experimental brain research·2019
Same author

Reduced vestibular function is associated with longer, slower steps in healthy adults during normal speed walking.

Gait & posture·2018
Same author

Muscle Quality, Strength, and Lower Extremity Physical Performance in the Baltimore Longitudinal Study of Aging.

The Journal of frailty & aging·2017
Same author

Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

The Journal of frailty & aging·2016
Same author

Editorial: Clinical and Biological Markers of Sarcopenia: Where Are We?

The Journal of frailty & aging·2016
Same journal

Associations of sarcopenia with the risk of incident respiratory disease and the role of inflammation and metabolism: a prospective cohort study.

The journal of nutrition, health & aging·2026
Same journal

Corrigendum to "Association of serum 25-hydroxyvitamin D with the risk of depression in individuals with prediabetes and diabetes: A prospective cohort study" [J Nutr Health Aging, 29 (2025) 100556].

The journal of nutrition, health & aging·2026
Same journal

Association between living arrangements in early old age and subsequent trajectories of protein intake among older adults in China.

The journal of nutrition, health & aging·2026
Same journal

Associations of adiponectin, leptin, and the adiponectin-to-leptin ratio with sarcopenia in older adults with cardiovascular-kidney-metabolic syndrome.

The journal of nutrition, health & aging·2026
Same journal

Association of artificial sweeteners intake and risk of CKD: a prospective cohort study.

The journal of nutrition, health & aging·2026
Same journal

Falls and frailty transitions in older adults: A multi-state analysis of a national longitudinal cohort.

The journal of nutrition, health & aging·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Target population for clinical trials.

S Studenski1

  • 1Pittsburgh Claude D. Pepper Center, PA, USA. sas33@pitt.edu

The Journal of Nutrition, Health & Aging
|August 7, 2009
PubMed
Summary
This summary is machine-generated.

Defining clinical trial populations for sarcopenia requires aligning treatment goals with the disease

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Related Experiment Videos

Last Updated: Jun 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Area of Science:

  • Gerontology and Geriatric Medicine
  • Muscle Physiology
  • Clinical Trial Design

Background:

  • Sarcopenia is characterized by loss of muscle mass and quality, leading to decreased strength, mobility, and functional independence.
  • The natural history of sarcopenia informs the development of both preventive and therapeutic interventions.
  • Identifying appropriate patient populations is crucial for successful clinical trials.

Purpose of the Study:

  • To outline the criteria for defining target populations in clinical trials for sarcopenia.
  • To emphasize the importance of treatment goals and natural disease progression in population selection.
  • To provide a framework for eligibility criteria considering treatment response, safety, prevalence, and feasibility.

Main Methods:

  • Review of sarcopenia natural history and its implications for treatment.
  • Analysis of potential treatment goals for preventive and therapeutic strategies.
  • Identification of key factors for clinical trial eligibility criteria.

Main Results:

  • Target populations can be stratified based on disease stage (e.g., pre-disability vs. mobility-impaired).
  • Treatment goals range from preventing mobility disability to improving function in affected individuals.
  • Eligibility criteria must balance potential treatment efficacy with safety, prevalence, and trial feasibility.

Conclusions:

  • Clinical trial design for sarcopenia necessitates a clear definition of the target population based on specific treatment objectives.
  • Eligibility criteria should be carefully selected to ensure patient safety and maximize the chances of detecting treatment effects.
  • A tailored approach to population selection is essential for advancing sarcopenia research and developing effective interventions.